中文摘要：

目前，国内辅助生殖技术中控制性超促排卵（controlled ovarian hyperstimulation，COH）仍以促性腺激素释放激素激动剂（gonadotropin releasing hormone agonist，GnRH—a）长方案为主，但GnRH—a长方案中的大剂量、长时间的促性腺激素（gonadotropin，Gn）暴露对卵泡的生长、卵子的发育不利。20世纪90年代，促性腺激素释放激素拮抗剂（gonadotropin releasing hormone antagonist，GnRH—A）开始用于人类辅助生殖技术（assisted reproductive technology，ART）。GnRH—A通过与垂体促性腺激素释放激素（gonadotropin releasing hormone，GnRH）受体结合，有效抑制早发黄体生成素（luteinizing hormone，LH）峰，具有起效快、作用时间短、停药后垂体恢复迅速等特点，然而其在不同卵巢功能患者超排中的应用尚存在争议。本文对GnRH—A在ART中的临床应用作一综述。

英文摘要：

Gonadotropin-releasing hormone agonists （GnRH-a）are widely used in controlled ovarian hyperstimulation （COH） at present in China. However, more and more studies show that long-term and large dose administration of GnRH-a would have an adverse effects on oocytes. Gonadotropin-releasing hormone antagonists （GnRH-A） have been used in human assisted reproduction technology （ART） since 1990s. As a competitive inhibitor of gonadotropin-releasing hormone （GnRH） receptors, GnRH-A can prevent the premature luteinizing hormone （LH） surge during COH, and GnRH-A has the advantages of fast action, short action duration and quick piruitary recovery. But it is controversial to use GnRH-A in patients with different ovarian responses. In this article, we will review the clinical application of GnRH-A in ART, focusing on its use in patients with different ovarian function.